Treating the condition is difficult - anaemia is a common side effect. A new drug, Momelotinib, approved by the Therapeutic Goods Administration in December, is giving patients hope.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.40. The company’s shares closed today ...

Learn More Pharmaceutical giant GSK is pushing the boundaries of what generative AI can achieve in healthcare areas like scientific literature review, genomic analysis and drug discovery.

The drug in question is Ojjaara (momelotinib), for the bone marrow cancer myelofibrosis. Developed by the formerly ASX-listed Cytopia, the drug changed ownership several times before GlaxoSmithKline ...

GSK won’t be hearing from the FDA this month about its marketing application for momelotinib as a treatment for myelofibrosis patients with anaemia after all. The pharma group said this morning ...

A high-profile team of architects, landscape designers, and consultants has been appointed to progress a masterplan for the redevelopment of the former GSK headquarters at 980 Great West Road, ...

Last month saw a number of alliances forming in a range of therapeutic spaces but there has been one serial collaborator that stands out – GSK. The British pharma giant seems to have embarked on a ...

Key stocks in focus include General Insurance Corp, ONGC, SpiceJet, GSK Pharma, and Cipla due to various developments. Notable updates include the government's stake sale in General Insurance Corp and ...

Momelotinib dihydrochloride is under clinical development by GSK and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid ...

The FDA has approved momelotinib (Ojjaara) for the treatment of adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, and anemia.